Market Overview

UPDATE: Stifel Nicolaus Initiates St. Jude Medical at Hold on Near-Term Headwinds

Related STJ
Barclays Likes Abbott Laboratories, Whether Acquisitions Close Or Not
Takeover Talk A Help To Wide-Moat ETFs
Medtronic Rounds Out Heart-Failure Offerings With HeartWare Buy (Investor's Business Daily)

Stifel Nicolaus initiated coverage on St. Jude Medical (NYSE: STJ) with a Hold rating.

Stifel Nicolaus said, "We are initiating coverage of St. Jude Medical Inc. (STJ) with a Hold rating on the shares. With top-line growth slowing and lingering uncertainties about the impact of the Riata/Durata ICD lead controversy resolution, a possible FDA Warning Letter, and no visible significant near-term positive catalyst, we are inclined to remain on the sidelines, pending greater visibility on these issues."

St. Jude Medical closed at $35.03 on Monday.

Latest Ratings for STJ

May 2016BarclaysDowngradesOverweightEqual-weight
May 2016SunTrust Robinson HumphreyDowngradesBuyNeutral
May 2016Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (STJ)

View Comments and Join the Discussion!